Abt-869. Linifanib has much less activity against unrelated rtks, soluble tyrosine kinases, or serine/threonine kinases. Linifanib shows prominent antitumor activity.
It has much less activity (ic50s > 1 μm). Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated rtks, soluble tyrosine kinases, or serine/threonine kinases.
It has much less activity (ic50s > 1 μm).
Linifanib is intended for the treatment. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated rtks, soluble tyrosine kinases, or serine/threonine kinases.
It is highly selective (> 1um) against unrelated tyrosine kinases and serine/threonine kinases.
Abt-869. Linifanib has much less activity against unrelated rtks, soluble tyrosine kinases, or serine/threonine kinases. Linifanib shows prominent antitumor activity.
It has much less activity (ic50s > 1 μm). Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated rtks, soluble tyrosine kinases, or serine/threonine kinases.
It has much less activity (ic50s > 1 μm).
Linifanib is intended for the treatment. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated rtks, soluble tyrosine kinases, or serine/threonine kinases.
Komentar
Posting Komentar